胰腺神经内分泌肿瘤放射性核素治疗

Radionuclide therapy for pancreatic neuroendocrine neoplasms

胰腺神经内分泌肿瘤(pNENs)是最常见的神经内分泌肿瘤。对于早期局限的pNENs,手术是主要的治疗手段并可达到治愈的效果,但对于无法手术切除或已经发生远处转移的pNENs,因pNENs常过表达生长抑素受体,肽受体介导的放射性核素治疗(peptide receptor radionuclide therapy,PRRT)或可作为一线治疗方案。近年来关于PRRT用于pNENs的临床试验研究逐年增多,许多报道证实了90Y及177Lu标记的生长抑素类似物在pNENs病人中的良好疗效。

Pancreatic neuroendocrine neoplasms(pNENs)are the most common neuroendocrine tumors.For early local pNENs,surgery is the main therapeutic strategy and the tumor can be removed completely.But for those pNENs that cannot be surgically removed or have undergone distant metastasis,peptide receptor radionuclide therapy(PRRT)can be chosen as a first-line therapeutic strategy as pNENs overexpress somatostatin receptors.In recent years,clinical trials and studies on the use of PRRT in pNENs have been increasing rapidly.Many reports have confirmed the efficacy of 90 Y and 177 Lu-labeled somatostatin analogue in pNENs patients.